May 19th 2025
The company's Nuvaxovid vaccine is the only recombinant protein-based, non-mRNA COVID-19 immunization available in the US.
May 15th 2025
Clinical-stage company, Biovie, will study its therapy, bezisterim, for treatment of neurological symptoms associated with the condition. The company expects to have study results in the first half of 2026.
May 7th 2025
In a large study, Moderna’s investigational vaccine, mRNA-1083, was shown to have noninferiority to other vaccines, and had an acceptable tolerability and safety profile.
May 5th 2025
Three different studies reveal blood signatures linked to symptoms, immune pathways tied to lung damage, and the efficacy of cognitive training for brain fog.
May 2nd 2025
The company had requested approval for its mRNA-1083 combination vaccine last year. With this setback, the company is now looking at 2026 for approval.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
EMA Recommends Updated Pfizer-BioNTech COVID-19 Vaccine
September 2nd 2023The European Medicines Agency (EMA) based its decision on preclinical data showing that the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine generates an improved response against multiple XBB-related sublineages, including XBB15, XBB116, XBB23, and EG51.
Read More
COVID-19's Impact on Alzheimer's: Uncovering 2 Years of Mortality Trends
July 17th 2023This study found a substantial increase in Alzheimer's-related deaths during the initial year of the pandemic due to limited access to healthcare, social isolation, and disrupted care routines. However, the second year brought positive developments with prevention strategies and vaccinations, leading to a substantial decline in excess deaths.
Read More
COVID-19 Vaccines Bridge Socioeconomic Disparities in Pandemic Impact, CDC Study Shows
July 13th 2023This study analyzed 81 communities in Los Angeles and found that once vaccines became widely available, there was no significant difference in COVID-19 incidence between communities of varying income levels.
Read More
Can Immunomodulators Reduce Recovery Time in Patients Hospitalized With COVID-19 Pneumonia?
July 11th 2023Researchers investigated abatacept, cenicriviroc, and infliximab, but found that these medications did not significantly impact the time to recovery from COVID-19 pneumonia compared to placebo.
Read More
Novavax as a Second Dose: A Potential Game Changer for Adolescent COVID-19 Vaccination
July 6th 2023The findings showed that heterologous vaccination, or mixing different vaccines, was safe and effective, with the Novavax vaccine (NVX-CoV2373) providing enhanced protection against the Omicron variant.
Read More
Using Comorbidities and Demographics to Predict COVID-19 Outcomes in the Midwest
June 27th 2023In Indiana, COVID-19 patients with chronic obstructive pulmonary disease, cardiovascular disease, and type 2 diabetes had significantly higher mortality rates than COVID-19 patients without these comorbidities.
Read More
2 Commerce Drive
Cranbury, NJ 08512